Thermo Fisher Scientific Inc. announced a 10-year virtual power purchasing agreement (VPPA) with X-ELIO, an international renewable energy developer, to increase access to renewable electricity across the pharmaceutical and healthcare supply chains. This agreement is designed to accelerate the company's goal of achieving 100 percent renewable electricity for its European operations.
Thermo Fisher’s 73 MW portion of the Lorca solar project, combined with the Serbal solar project announced in December 2023, will match all of the company’s addressable European sites with 100 percent renewable electricity. This project also advances progress toward the company’s broader goal of achieving 80 percent global renewable electricity by 2030.
The Lorca solar project is expected to be operational in early 2026 and includes a cohort of three partners from the pharmaceutical and healthcare sectors: GSK, Gilead Sciences, and Haleon. Thermo Fisher, as the cohort lead for this agreement facilitated by the Energize initiative, is committed to leveraging its experience to enable similar milestones for its partners, reducing Scope 2 and Scope 3 emissions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.